# US 2021/0061882 A1 · Mutant g-protein coupled receptors and methods for selecting them

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0061882 A1
- Document ID: US20210061882A1
- Status: Published application
- Kind: A1
- Application number: 16/871,254
- Filed: 2020-05-11
- Published: 2021-03-04
- Earliest claimed: 2007-03-22
- Assignees: Heptares Therapeutics Limited
- Applicants: Heptares Therapeutics Limited
- Inventors: Richard Henderson; Christopher Gordon Tate; Francesca Magnani; Maria Josefa Serrano-Vega; Yoko Shibata; Antony Johannes Warne; Malcolm Peter Weir
- Web page: https://patentgrep.com/patent/US20210061882A1

## CPC

- C07K 14/723: {G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor}
- C12N 15/1034: {Isolating an individual clone by screening libraries}
- G01N 33/566: using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds}
- G01N 2333/726: G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention relates to mutant G-protein coupled receptors with increased conformational stability, and methods of use thereof. In some aspects, polynucleotides encoding the mutant G-protein coupled receptors are provided. In some aspects, host cells comprising the polynucleotides are provided. In some aspects, the invention relates to crystallized forms of the mutant G-protein coupled receptors, and methods of preparing the same.

## Claims

### Claim 1

A mutant G-protein coupled receptor (GPCR) with increased conformational stability compared to its parent GPCR, which mutant GPCR has an extended lifetime of a particular conformation relative to the same conformation of its parent GPCR under denaturing conditions, the extended lifetime being manifest by retention of ligand binding ability.

### Claim 2 (depends on 1)

A mutant GPCR according to claim 1, wherein the mutant GPCR has an extended lifetime under conditions selected from any one or more of heat, a detergent, a chaotropic agent and an extreme of pH.

### Claim 3 (depends on 2)

A mutant GPCR according to claim 2, wherein the mutant GPCR has increased conformational thermostability, optionally which is at least 1° C. more stable than its parent.

### Claim 4 (depends on 1)

A mutant GPCR according to claim 1, with increased conformational stability of an agonist or antagonist conformation.

### Claim 5 (depends on 1)

A mutant GPCR according to claim 1, wherein the mutant GPCR is a Class 1 GPCR.

### Claim 6 (depends on 1)

A mutant GPCR according to claim 1, wherein the mutant GPCR is a Class 2 GPCR.

### Claim 7 (depends on 1)

A mutant GPCR according to claim 1, wherein the mutant GPCR is a Class 3 GPCR.

### Claim 8 (depends on 1)

A polynucleotide encoding a mutant GPCR according to claim 1.

### Claim 9 (depends on 8)

A host cell comprising a polynucleotide according to claim 8.

### Claim 10 (depends on 1)

A mutant GPCR according to claim 1, which is in a solubilized form.

### Claim 11 (depends on 1)

A mutant GPCR according to claim 1, which is substantially free of other proteins.

### Claim 12 (depends on 1)

A mutant GPCR according to claim 1, which is immobilized to a solid support.

### Claim 13 (depends on 1)

A mutant GPCR according to claim 1, wherein the mutant GPCR is not a human cannabinoid receptor.

### Claim 14 (depends on 8)

A polynucleotide according to claim 8, wherein the mutant GPCR is not a human cannabinoid receptor.

### Claim 15 (depends on 9)

A host cell according to claim 9, wherein the mutant GPCR is not a human cannabinoid receptor.

### Claim 16 (depends on 1)

A crystallized form of a mutant GPCR according to claim 1.

### Claim 17 (depends on 1)

A method comprising crystallizing a mutant GPCR of claim 1.

### Claim 18 (depends on 1)

A method comprising
obtaining a mutant GPCR of claim 1, and
screening for a ligand that binds to the mutant GPCR.

### Claim 19 (depends on 18)

The method of claim 18, wherein the mutant GPCR is coupled to a solid surface of a biosensor chip.

### Claim 20 (depends on 1)

A method comprising
obtaining a mutant GPCR of claim 1, and
developing an assay involving binding of a ligand to the mutant GPCR.
